InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

- Current share price for OSL : $1.210

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 OncoSil Medical Presents at Asia BiotechInvest 4 May 2016 9:14AM $0.145 $1.210 risen by 734.48%
$37 Appendix 4C - Quarterly Cashflow 28 Apr 2016 9:28AM $0.145 $1.210 risen by 734.48%
$37 OncoSil Medical Change of Address 19 Apr 2016 9:36AM $0.165 $1.210 risen by 633.33%
$37 Cleansing Notice and Appendix 3B 15 Apr 2016 4:11PM $0.165 $1.210 risen by 633.33%
$37 OncoSil EGM Notice of Meeting 8 Apr 2016 11:17AM $0.155 $1.210 risen by 680.65%
$37 OncoSil Medical releases latest Investor Presentation 23 Mar 2016 4:31PM $0.160 $1.210 risen by 656.25%
$37 Withdrawal of Extraordinary General Meeting 22 Mar 2016 9:24AM $0.150 $1.210 risen by 706.67%
$37 OncoSil Market Update March 1 1 Mar 2016 9:30AM $0.160 $1.210 risen by 656.25%
$37 Notice of Extraordinary General Meeting/Proxy Form 25 Feb 2016 9:16AM $0.160 $1.210 risen by 656.25%
$37 Appendix 4D & Half Year Accounts 15 Feb 2016 9:29AM $0.195 $1.210 risen by 520.51%
$37 Notice of change of substantial holder 11 Feb 2016 10:41AM $0.190 $1.210 risen by 536.84%
$37 Ceasing to be a substantial holder 11 Feb 2016 10:40AM $0.190 $1.210 risen by 536.84%
$37 Cleansing Notice & Appendix 3B 10 Feb 2016 9:36AM $0.200 $1.210 risen by 505%
$37 Becoming a substantial holder 9 Feb 2016 5:21PM $0.200 $1.210 risen by 505%
$37 $10 Million Institutional Placement 3 Feb 2016 9:22AM $0.225 $1.210 risen by 437.78%
$37 Notification of change of Share Registry 29 Jan 2016 9:18AM $0.245 $1.210 risen by 393.88%
$37 Appendix 4C - Quarterly Cashflow 28 Jan 2016 9:26AM $0.245 $1.210 risen by 393.88%
$37 Initial Directors interest 25 Jan 2016 9:45AM $0.260 $1.210 risen by 365.38%
$37 OncoSil Medical Cleansing Notice & Appendix 3B 21 Jan 2016 8:52AM $0.225 $1.210 risen by 437.78%
$37 Dr Chris Roberts - appointed Non-Executive Director 21 Jan 2016 8:48AM $0.225 $1.210 risen by 437.78%
$37 Appendix 3B 13 Jan 2016 9:54AM $0.235 $1.210 risen by 414.89%
$37 Share Option Vesting Conditions Met 7 Jan 2016 4:17PM $0.215 $1.210 risen by 462.79%
$37 Share Option Vesting Conditions Met 23 Dec 2015 10:09AM $0.250 $1.210 risen by 384%
$37 Appendix 3F updated 23 Dec 2015 10:02AM $0.250 $1.210 risen by 384%
$37 OncoSil Medical appoints Charles Rowland President - USA 15 Dec 2015 9:48AM $0.155 $1.210 risen by 680.65%

701 - 725 of 791 results

Page 29 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.